-
1دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://www.hal.inserm.fr/inserm-03831070Test; https://www.hal.inserm.fr/inserm-03831070/documentTest; https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://www.hal.inserm.fr/inserm-03831070Test
https://www.hal.inserm.fr/inserm-03831070/documentTest
https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
2
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Paediatric Nephrology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ARD - Amsterdam Reproduction and Development, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, CarMeN, laboratoire, Texas Children's Hospital [Houston, USA], Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center [Nahariya, Israel], Bar-Ilan University [Israël], Mayo Clinic [Rochester], Shaare Zedek Medical Center [Jerusalem, Israel], Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Cliniques Universitaires Saint-Luc [Bruxelles], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France [Beirut, Lebanon] (2HDF), Jordan University of Science and Technology [Irbid, Jordan] (JUST), Canberra Health Services [Garran, ACT, Australia] (CHS), Alnylam Pharmaceuticals [Cambridge, MA, USA], Rambam Health Care Campus [Haifa, Israel]
المصدر: American journal of kidney diseases, 81(2), 145-155.e1. W.B. Saunders Ltd
American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 81, no.2, p. 145-155.e1 (2023)
American Journal of Kidney Diseases, (2022)
American Journal of Kidney Diseases
American Journal of Kidney Diseases, 2022, S0272-6386 (22), pp.00771-5. ⟨10.1053/j.ajkd.2022.05.012⟩مصطلحات موضوعية: Adult, Male, RNA interference (RNAi), safety, Lumasiran, urinary oxalate (UOx), Adolescent, [SDV]Life Sciences [q-bio], kidney disease, efficacy, Young Adult, nephrocalcinosis, glycolate, pharmacodynamics, Humans, Child, Hyperoxaluria, Oxalates, systemic oxalosis, hemodialysis, cardiac dysfunction, phase 3 clinical trial, Infant, Newborn, Infant, Middle Aged, adverse events, primary hyperoxaluria type 1 (PH1), [SDV] Life Sciences [q-bio], plasma oxalate (POx), anti-drug antibodies, pediatric, Nephrology, Child, Preschool, Hyperoxaluria, Primary, Female, Kidney Diseases, pharmacokinetics
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e766f52870784a99182763b902908469Test
https://doi.org/10.1053Test/j .ajkd.2022.05.012